IL13 and conjunctivitis: The cause of dupilumab-associated conjunctivitis, as well as the relationship between its various pathogenetic mechanisms, are currently unclear, but possible hypotheses include inhibition of IL-4 and IL-13 signaling pathways involved in the development of atopic keratoconjunctivitis.